Persistence of the neutralizing antibody response after SARS-CoV-2 infection

被引:7
|
作者
Shim, Sang-Mu [1 ]
Kim, Jun-Won [2 ]
Jung, Sunhee [2 ]
Jung, Yujung [2 ]
Woo, Hye-Min [2 ]
Yang, Jeong-Sun [2 ]
Kim, Kyung-Chang [2 ]
Lee, Joo-Yeon [3 ]
机构
[1] Korea Dis Control & Prevent Agcy, Korea Natl Inst Hlth, Div Acute Virus Dis, Cheongju, South Korea
[2] Korea Dis Control & Prevent Agcy, Div Emerging Virus & Vector Res, Korea Natl Inst Hlth, Cheongju, South Korea
[3] Korea Dis Control & Prevent Agcy, Korea Natl Inst Hlth, Ctr Emerging Virus Res, 187 Osongsaengmyeong2-ro, Cheongju 28159, Chungcheongbuk, South Korea
关键词
COVID-19; ELISA; Neutralizing antibody; Plaque-reduction neutralizing test; SARS-CoV-2;
D O I
10.1016/j.cmi.2021.12.012
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objective: Neutralizing antibodies are among the factors used to measure an individual's immune status for the control of infectious diseases. We aimed to confirm the persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibody levels in patients who had recovered from coronavirus disease 2019 (COVID-19). Methods: Plasma donors in South Korea who had completely recovered from SARS-CoV-2 infection had follow-up testing to determine the persistence of neutralizing antibodies using a plaque-reduction neutralization test and ELISA. Results: Of the 111 participants-aged 20-29 years, 37/111 (33.3%); 30-39 years, 17/111 (15.3%); 40 -49 years, 23/111 (20.7%); 50-59 years, 21/111 (18.9%); 60-65 years, 13/111 (11.7%); male, 43/111 (38.7%); female, 68/111 (61.3%)-66.1% still had neutralizing antibodies approximately 9 months (range 255-302 days) after confirmation of the diagnosis. Conclusions: In this study we analysed the titre of neutralizing antibodies associated with predicting immune status in individuals with natural infection. Information about the persistence and change in levels of neutralizing antibodies against SARS-CoV-2 can be utilized to provide evidence for developing vaccination schedules for individuals with previous infection. (C) 2022 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.
引用
收藏
页码:614.e1 / 614.e4
页数:4
相关论文
共 50 条
  • [1] Persistence of Neutralizing Antibody Response up to 1 Year After Asymptomatic or Symptomatic SARS-CoV-2 Infection
    Choe, Pyoeng Gyun
    Kang, Chang Kyung
    Kim, Kye-Hyung
    Yi, Jongyoun
    Kim, Eu Suk
    Park, San Won
    Kim, Nam Joong
    Park, Wan Beom
    Oh, Myoung-don
    JOURNAL OF INFECTIOUS DISEASES, 2021, 224 (06): : 1097 - 1099
  • [2] Persistence of Neutralizing Antibody Response up to 1 Year After Asymptomatic or Symptomatic SARS-CoV-2 Infection Reply
    Ma, Mai-Juan
    JOURNAL OF INFECTIOUS DISEASES, 2021, 224 (06): : 1099 - 1100
  • [3] Persistence of neutralizing antibodies a year after SARS-CoV-2 infection in humans
    Haveri, Anu
    Ekstrom, Nina
    Solastie, Anna
    Virta, Camilla
    Osterlund, Pamela
    Isosaari, Elina
    Nohynek, Hanna
    Palmu, Arto A.
    Melin, Merit
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2021, 51 (12) : 3202 - 3213
  • [4] Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans
    Vanshylla, Kanika
    Di Cristanziano, Veronica
    Kleipass, Franziska
    Dewald, Felix
    Schommers, Philipp
    Gieselmann, Lutz
    Gruell, Henning
    Schlotz, Maike
    Ercanoglu, Meryem S.
    Stumpf, Ricarda
    Mayer, Petra
    Zehner, Matthias
    Heger, Eva
    Johannis, Wibke
    Horn, Carola
    Suarez, Isabelle
    Jung, Norma
    Salomon, Susanne
    Eberhardt, Kirsten Alexandra
    Gathof, Birgit
    Faetkenheuer, Gerd
    Pfeifer, Nico
    Eggeling, Ralf
    Augustin, Max
    Lehmann, Clara
    Klein, Florian
    CELL HOST & MICROBE, 2021, 29 (06) : 917 - +
  • [5] Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination
    Dapporto, Francesca
    Marchi, Serena
    Leonardi, Margherita
    Piu, Pietro
    Lovreglio, Piero
    Decaro, Nicola
    Buonvino, Nicola
    Stufano, Angela
    Lorusso, Eleonora
    Bombardieri, Emilio
    Ruello, Antonella
    Viviani, Simonetta
    Molesti, Eleonora
    Trombetta, Claudia Maria
    Manenti, Alessandro
    Montomoli, Emanuele
    JOURNAL OF IMMUNOLOGY RESEARCH, 2022, 2022
  • [6] Impact of SARS-CoV-2 infection during pregnancy and persistence of antibody response
    Zelini, Paola
    Perotti, Francesca
    Scatigno, Annachiara Licia
    Dominoni, Mattia
    Zavaglio, Federica
    Arossa, Alessia
    Piccini, Stefania
    Angelini, Micol
    Ghirardello, Stefano
    Lilleri, Daniele
    Baldanti, Fausto
    Spinillo, Arsenio
    NEW MICROBIOLOGICA, 2022, 45 (03): : 181 - 189
  • [7] The Antibody Response to SARS-CoV-2 Infection
    Hueston, Linda
    Kok, Jen
    Guibone, Ayla
    McDonald, Damien
    Hone, George
    Goodwin, James
    Carter, Ian
    Basile, Kerri
    Sandaradura, Indy
    Maddocks, Susan
    Sintchenko, Vitali
    Gilroy, Nicole
    Chen, Sharon
    Dwyer, Dominic E.
    O'Sullivan, Matthew V. N.
    OPEN FORUM INFECTIOUS DISEASES, 2020, 7 (09):
  • [8] Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection
    Lau, Eric H. Y.
    Hui, David S. C.
    Tsang, Owen T. Y.
    Chan, Wai-Hung
    Kwan, Mike Y. W.
    Chiu, Susan S.
    Cheng, Samuel M. S.
    Ko, Ronald Lw
    Li, John K. C.
    Chaothai, Sara
    Tsang, Chi H.
    Poon, Leo L. M.
    Peiris, Malik
    ECLINICALMEDICINE, 2021, 41
  • [9] Neutralizing Antibody Response of Vaccinees to SARS-CoV-2 Variants
    Anichini, Gabriele
    Terrosi, Chiara
    Savellini, Gianni Gori
    Gandolfo, Claudia
    Franchi, Federico
    Cusi, Maria Grazia
    VACCINES, 2021, 9 (05)
  • [10] Longitudinal antibody titer, avidity, and neutralizing responses after SARS-CoV-2 infection
    Monroe, Jonathon M.
    Haralambieva, Iana H.
    Warner, Nathaniel D.
    Grill, Diane E.
    Quach, Huy Quang
    Kennedy, Richard B.
    HELIYON, 2022, 8 (11)